New developments in the treatment of metastatic gastric cancer: focus on trastuzumab

Jeffrey S Rose  
Tanios S Bekaii-Saab

Department of Internal Medicine,  
Division of Medical Oncology,  
The Ohio State University – Arthur James Cancer Hospital, Columbus, OH, USA

Abstract: Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has been found to improve response rate and survival in patients with advanced gastric cancer. This update will review the role of HER2 and summarize therapeutic advances in the use of trastuzumab in advanced gastric cancer.

Keywords: gastric, gastroesophageal, adenocarcinoma, chemotherapy, trastuzumab

Introduction

In 2010, it is estimated that 21,000 men and women will be diagnosed with gastric cancer in the United States. During the same year, 10,570 will die of this disease. Worldwide, gastric cancer is the fourth most common cancer and the second most common cause of cancer death. The incidence of cardiac and gastroesophageal tumors has increased dramatically, while cancers in the distal half of the stomach have declined in the United States since the 1930s. Additionally, patient demographics have shifted with a marked increase in incidence in younger patients. With approximately 80% of patients presenting with advanced disease, palliative chemotherapy plays an essential role in the treatment of these cancers.

Gastric cancer remains highly fatal with only modest gains in survival having been achieved with modern chemotherapy. To date, there is no standard chemotherapeutic option for patients with metastatic gastric cancer. Cisplatin and 5-fluorouracil typically combined with either a taxane or an anthracycline comprise the most common treatment regimens.

Targeted therapy, including inhibitors of the vascular endothelial and epidermal growth factor receptors, appears to be promising. Human epidermal growth factor receptor-2 (ErbB2 or HER2) is a well-established target that has been studied extensively in gastric cancer. Trastuzumab (Herceptin®, F. Hoffman-La Roche, Basel, Switzerland), a fully humanized monoclonal antibody directed against HER2, is a standard therapy for patients with HER2 positive breast cancer, after studies demonstrated improved survival and response rates. This review will focus on the role of HER2 and its inhibition with trastuzumab in advanced gastric cancer.
The human epidermal growth factor receptor-2 (HER2)

Epidermal growth factor and its receptor (EGFR or ErbB) were initially discovered in 1962 and 1978, respectively. The ErbB family consists of four closely related type 1 transmembrane tyrosine kinase receptors: ErbB1 (EGFR or HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). Each receptor is a transmembrane protein comprising an extracellular domain at which ligand binding occurs, an alpha-helical transmembrane segment, and an intracellular protein tyrosine kinase domain. Ligand binding to these EGF family receptors phosphorylates and activates a complex intracellular signaling network, which controls a range of cellular processes including proliferation, angiogenesis, cell cycle, survival, and apoptosis.

HER2 was the second receptor discovered in this family. Structurally, HER2 is a 185 kD glycoprotein and a product of the c-erbB-2/neu oncogene. As opposed to the other members of the EGFR family, no ligand has been linked to HER2. Researchers believe that the receptor must homodimerize independently of a ligand, or heterodimerize with another ligand-bound member of the EGFR family for activation. Ligand-independent homodimerization will occur in the setting of HER2 overexpression. Activation leads to autophosphorylation of the intracellular tyrosine kinase domain and downstream signaling of the RAS, MAP, and PI3K pathways. HER2 amplification and overexpression plays a central role in disease initiation, progression, and metastasis, and is traditionally associated with a worse prognosis in patients with breast and gastric cancers.

HER2 in gastric cancer

Amplification of HER2 was described in a gastric cancer cell line initially in 1986. In 1991, initial clinical findings were published by Yonemura and colleagues documenting HER2 overexpression to be detected by immunohistochemistry in 11.9% of 260 Japanese gastric cancer patients. Many subsequent studies have found amplification or overexpression of HER2 in 7% to 34% of gastric carcinomas. Histologically, HER2 overexpression is more often associated with differentiated tumors as well as intestinal-type tumors both of which would imply a more favorable outcome. In the ToGA trial, which will be discussed later, HER2 overexpression was far more common in intestinal-type (75%) than diffuse-type (9%) tumors. The correlation of intestinal-type histology and HER2 overexpression is not well understood but may be partially explained by E-cadherin mutations. In gastric cancer, HER2 gene amplification associates inversely with E-cadherin mutations, which are more common in diffuse-type gastric and lobular invasive breast carcinomas and rare in intestinal-type gastric and ductal invasive breast carcinomas. In addition, germline mutations of E-cadherin have been identified that are responsible for a dominantly inherited form of diffuse-type gastric cancer. However, HER2 overexpression is more often associated with higher T-stage and nodal involvement at time of diagnosis, which are poor prognostic factors. HER2 overexpressing tumors are most often in the located gastroesophageal junction (33.2%) rather than the remainder of the stomach (20.9%).

Historically, HER2 overexpression was associated with a significantly worse overall survival. Multiple series confirm these findings. However, a recently published European series as well as two Asian series found that HER2 overexpression does not impact prognosis. Indeed, the patients treated in the chemotherapy alone arm of the ToGA trial survived to a median of 11.1 months, which is equivalent if not superior to historic comparisons. Therefore, the impact of HER2 overexpression on survival remains unclear, and arguably has little impact.

There has been a concerted effort to standardize HER2 assessment in gastric carcinoma. Compared with breast carcinoma, HER2 immunoreactivity in gastric carcinoma is more incomplete and heterogeneous. Additionally, HER2 staining results appear to differ by type of specimen, ie, endoscopic biopsy compared with surgically resected specimens. Hoffman and colleagues have developed and validated a scoring system for assessing HER2 in gastric carcinomas. Assessment of 168 resection specimens (149 from the stomach and 16 from the gastroesophageal junction) was performed using immunohistochemistry by HecepTest (Dako, Denmark) and fluorescence in-situ hybridization (FISH) by HER2 FISH (pharmDx™, Dako, Denmark). Twenty-nine samples were considered FISH positive (defined as HER2:CEP17 ratio ≥2), while 18 samples were considered positive with IHC 3+. All 18 samples positive by IHC were positive by FISH, however FISH identified another 11 patients which were considered negative (IHC 0 or 1+) or equivocal (IHC 2+). Discrepancies between IHC and FISH results were attributed to basolateral membranous immunoreactivity of glandular cells resulting in incomplete membranous reactivity along with a higher rate of tumor heterogeneity. Based on the findings of this study, a consensus panel has proposed recommendations on HER2 scoring for gastric cancer (Table 1).
Clinical trials using trastuzumab

The results of a study combining trastuzumab with cisplatin in HER2 positive untreated patients with gastric cancer have recently been presented. Twenty-one patients with advanced gastric or gastroesophageal carcinoma were enrolled. Overall the response rate was reported at 35% in 17 evaluable patients with final results on survival not available yet. Another study evaluating the role of trastuzumab in the treatment of previously untreated advanced gastric cancer in combination with cisplatin and docetaxel is underway with evidence of preliminary activity. Two hundred and ninety-six patients were randomized to the chemotherapy alone arm and 298 patients to the chemotherapy with trastuzumab arm. Median follow-up was 18.6 months in the trastuzumab plus chemotherapy arm and 17.1 months in the chemotherapy alone arm. The study met its primary endpoint with a median overall survival of 13.8 months in the chemotherapy with trastuzumab arm compared with 11.1 months in the chemotherapy alone arm (P = 0.0046). All other efficacy parameters were also significantly improved with the addition of trastuzumab to chemotherapy compared with chemotherapy alone (Table 2). It should be noted that the control arm group fared better than historic comparisons. This result may be related to the large proportion of Asian patients enrolled in the study, or more likely the presence of a high rate of intestinal-type histology in the study population. Seventy-seven percent of the experimental group and 74% of the control group were found to have intestinal-type histology, which is typically associated with better prognosis than diffuse-type histology. Unlike previously published data, these findings suggest that tumors overexpressing HER2 may have an equivalent if not favorable prognostic effect.

Therapy was very well tolerated with expected hematologic and gastrointestinal toxicities. The most common side effects were nausea, vomiting, and neutropenia. Patients assigned to trastuzumab plus chemotherapy had slightly higher rates

Table 1 HER2 immunohistochemical staining classification

<table>
<thead>
<tr>
<th>Surgical specimen staining pattern</th>
<th>Biopsy specimen staining pattern</th>
<th>Classification/score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No reactivity or membranous reactivity in &lt; 10% of tumor cells</td>
<td>No reactivity or no membranous reactivity in any tumor cell</td>
<td>Negative/0</td>
</tr>
<tr>
<td>Faint or barely perceptible membranous reactivity in ≥ 10% of tumor cells; cells are reactive only in part of membrane</td>
<td>Tumor cell cluster with faint or barely perceptible membranous reactivity irrespective of percentage of tumor cells stained</td>
<td>Negative/1+</td>
</tr>
<tr>
<td>Weak to moderate complete, basolateral or lateral membranous reactivity in ≥ 10% of tumor cells</td>
<td>Tumor cell cluster with a weak to moderate complete, basolateral or lateral membranous reactivity irrespective of percentage of tumor cells stained</td>
<td>Equivocal/2+</td>
</tr>
<tr>
<td>Strong complete, basolateral or lateral membranous reactivity in ≥ 10% of tumor cells</td>
<td>Tumor cell cluster with a strong complete, basolateral or lateral membranous reactivity irrespective of percentage of tumor cells stained</td>
<td>Positive/3+</td>
</tr>
</tbody>
</table>

of diarrhea, stomatitis, anemia, thrombocytopenia, fatigue, chills, weight loss, pyrexia, mucositis, and nasopharyngitis. With the exception of diarrhea, rates of grade 3 and 4 adverse events as well as cardiac adverse events were similar between the groups. Eleven patients (5%) experienced a $\geq 10\%$ decrease in left ventricular ejection fraction, and up to $< 50\%$ in the trastuzumab and chemotherapy group compared, with two patients (1%) in the chemotherapy alone group. The addition of trastuzumab to chemotherapy did not adversely affect quality of life.29

**Future directions**

The use of trastuzumab in gastric carcinomas is in its infancy and many avenues await exploration. As discussed previously, in advanced gastric carcinoma, trastuzumab has only been studied in combination with cisplatin and 5-FU in the Phase III setting, leading to FDA approval in the United States. However, in advanced HER2-overexpressing breast cancers, trastuzumab is very active in combination with taxanes, a class of chemotherapy active in gastric carcinoma.30–32 A pivotal Phase III trial published in 2001 combined trastuzumab with paclitaxel in patients with breast cancer previously treated with anthracyclines.1 In comparison to single-agent paclitaxel, the combination of paclitaxel and trastuzumab was associated with a significantly higher response rate of 38% vs 16% as well as a 4-month improvement in time to progression. There was also a nonsignificant increase in overall survival from 18 to 22 months. In addition, multiple Phase II studies have suggested superiority of the combination of docetaxel and trastuzumab compared with docetaxel alone.33–35 Many consider the combination of a taxane and trastuzumab to represent the best first-line option for women with hormone refractory HER2-overexpressing metastatic breast cancer. In our opinion, similar findings will be found in HER2-overexpressing gastric carcinomas, but we cannot endorse the use of trastuzumab with taxanes in the absence of data. Currently, an ongoing Phase II clinical trial is evaluating trastuzumab in combination with docetaxel, cisplatin, and 5-FU (ClinicalTrials.gov number NCT00515411) which may shed some light on this subject. Agents being evaluated in combination with trastuzumab for advanced gastric carcinomas include capcitabine and oxaliplatin, cisplatin and TS-One, and bevacizumab among others.

Resistance to trastuzumab will invariably develop in patients with advanced cancers being treated with trastuzumab-containing regimens. Indeed, the rate of primary resistance to single-agent trastuzumab in HER2-overexpressing metastatic breast carcinomas is 66%–88%.36–38 The conventional wisdom of discontinuing a cytotoxic agent upon progression has yet to be elucidated for novel biologics, and whether trastuzumab treatment should be continued upon progression with a different chemotherapeutic agent has not yet been established. Just as we do not fully understand the mechanisms of action of trastuzumab, we have even less understanding of the mechanisms of resistance. Proposed mechanisms of resistance include activation of multiple downstream signaling pathways such as P13K/AKT pathway which may occur with or without loss of the PTEN tumor suppressor gene,39 activation of non-HER2 receptors such as insulin-like growth factor-I,40 disruption of the interaction between the therapeutic agent and the target protein through increased expression of membrane-associated glycoprotein (MUC4),41 and loss of the binding site on truncated HER2 receptors.42 Retrospective studies suggest that trastuzumab administration is indicated after disease progression attributed to an increase in response rate as well as survival. A systematic review revealed that the response rate of second-line therapy along with continuation of trastuzumab was 21% with a time to progression of 6.7 months which appear promising.43 A recently published observational study of 623 patients found the median time to progression was longer in patients who continued trastuzumab beyond progression (10.2 months) than in those who stopped (7.1 months).44 Attempts to answer this question via phase III trials have been unsuccessful, plagued by slow accrual out of reluctance by caregivers and patients to discontinue trastuzumab. SWOG 0347 as well as the German Breast Group 26/Breast International Group 03–0545 studies were closed early, secondary to poor accrual. In the latter trial, analysis of

### Table 2 Results of trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2 positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Trastuzumab plus chemotherapy</th>
<th>Chemotherapy alone</th>
<th>P value (nonstratified)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall survival</td>
<td>13.8 months</td>
<td>11.1 months</td>
<td>0.0046</td>
</tr>
<tr>
<td>Progression-free survival</td>
<td>6.7 months</td>
<td>5.5 months</td>
<td>0.0002</td>
</tr>
<tr>
<td>Time to progression</td>
<td>7.1 months</td>
<td>5.6 months</td>
<td>0.0003</td>
</tr>
<tr>
<td>Duration of response</td>
<td>6.9 months</td>
<td>4.8 months</td>
<td>$&lt;0.0001$</td>
</tr>
<tr>
<td>Overall response rate</td>
<td>47%</td>
<td>35%</td>
<td>0.00175</td>
</tr>
</tbody>
</table>
156 of a planned 482 patients revealed a response rate of 27% and 48% in patients who stopped and continued trastuzumab, respectively. Trastuzumab use beyond progression was associated with a 31% reduction of tumor progression and increase in time to progression of 2.5 months. No studies have addressed this question in gastric carcinoma.

Lapatinib (GlaxoSmithKline, Research Triangle Park, NC, USA), an oral small molecule dual tyrosine kinase inhibitor of EGFR and HER2, has been found to be active in HER2-overexpressing cancers. In those with trastuzumab-refractory breast cancer, lapatinib combined with capecitabine had a response rate of 22% and statistically improved time to progression from 4.4 months in the lapatinib alone group to 8.4 months in the combination arm.46 Lapatinib in combination with chemotherapy is being assessed in advanced gastric carcinoma. The Phase III LOGiC trial (NCT00680901) is evaluating the combination of lapatinib in combination with capecitabine and oxaliplatin for first-line HER2-overexpressing gastric carcinomas. The study is actively accruing patients and no efficacy results are available to date. Safety analysis from TYTAN, a Phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in HER2 overexpressing gastric cancer, revealed no safety issues.47 Efficacy results are not yet available.

This review has focused on advanced disease. As seen in breast cancer, trastuzumab is an integral part of adjuvant or neoadjuvant treatment of operable disease. Perioperative chemotherapy using epirubicin, cisplatin, and 5-fluorouracil has been shown to improve survival in operable disease over surgery alone.48 A recent Phase III study, RTOG 1010, is evaluating the addition of trastuzumab to trimodality treatment of HER2-overexpressing esophageal adenocarcinoma.

**Conclusion**

HER2 overexpression in gastric cancer has been traditionally associated with poor survival, although results from recent studies such as the ToGA trial, appear to contradict this. HER2 targeted therapy with trastuzumab, when combined with chemotherapy (cisplatin and a fluoropyrimidine) has been shown to improve response rate, and progression-free and overall survival compared with chemotherapy alone in patients with advanced gastric or gastroesophageal adenocarcinomas, which overexpress HER2 (IHC 3+ and/or FISH+). In addition to improved outcome, trastuzumab combined with chemotherapy was found to be tolerable with no negative impact on quality of life. As such, trastuzumab should play an integral part in the management of patients with HER2-overexpressing advanced gastric adenocarcinoma. Current studies are evaluating the role of this combined approach in the perioperative setting. Future studies are needed to address the question of how to proceed upon disease progression while on trastuzumab.

**Disclosure**

Jeffrey S Rose: None. Tanios S Bekaii-Saab: Consulting fees and grant support from Genentech.

**References**


